The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Role of Galectin-3 in Human Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Galectin-3 is a beta-galactoside-binding protein which is implicated in diverse physiological and pathological processes including human liver cirrhosis and a mouse lung fibrosis model. The aim of this study is to determine whether galectin-3 is involved in human lung fibrosis. METHODS: We measured galectin-3 concentration in bronchoalveolar lavage fluid (BALF) and examined its expression in alveolar macrophages from patients with interstitial lung disorders using ELISA and immunohistochemical staining, respectively. Using monocyte/macrophage cell lines in vitro, we examined the effect of cytokines on galectin-3 expression, and the opposite similarly by RT-PCR and Western blotting. Finally, we performed Micro Boyden chamber assay and Sircoll assay to determine whether galectin-3 induces migration and collagen synthesis, respectively, in fibroblasts. RESULTS: Galectin-3 was specifically increased in BALF from patients with idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia associated with collagen vascular disease (CVD-IP). Galectin-3 levels in BALF seemed to be lower in IPF and CVD-IP patients receiving corticosteroid therapy. Alveolar macrophages from IPF patients expressed more galectin-3 compared with those from control. Galectin-3 expression was induced by tumor necrosis factor-alpha (TNF-alpha) and interferon (IFN)-gamma in a monocytic cell line U937. Galectin-3 also induced mRNA expression and protein production of TNF-alpha and interleukin (IL)-8 in a macrophage cell line THP-1. This lectin stimulated NIH-3T3 fibroblast to induce migration and collagen synthesis in vitro. CONCLUSIONS: These results suggest that galectin-3 is involved in the pathogenesis of human IPF and CVD-IP by activating macrophages and fibroblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
Demetriou, M., Granovsky, M., Quaggin, S., & Dennis, J. W. (2001) · Nature · doi:10.1038/35055582 · Cited by 901
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Critical role of galectin-3 in phagocytosis by macrophages
Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F.-T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317592 · Cited by 429
Cited by
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., Larson, M. G., & Levy, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.053 · Cited by 589
Galectin-3: A Novel Mediator of Heart Failure Development and Progression
de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp097 · Cited by 524
The regulation of inflammation by galectin‐3
Henderson, N. C., & Sethi, T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00794.x · Cited by 522
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Shah, R. V., Chen-Tournoux, A. A., Picard, M. H., van Kimmenade, R. R. J., & Januzzi, J. L. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq091 · Cited by 326
Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?
Byrne, A. J., Maher, T. M., & Lloyd, C. M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.004 · Cited by 315
The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens
Díaz-Alvarez, L., & Ortega, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/9247574 · Cited by 262
Functions of Galectin-3 and Its Role in Fibrotic Diseases
Li, L.-C., Li, J., & Gao, J. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218370 · Cited by 261
Galectin-3 in Cardiac Remodeling and Heart Failure
de Boer, R. A., Yu, L., & van Veldhuisen, D. J. (2010) · Current Heart Failure Reports · doi:10.1007/s11897-010-0004-x · Cited by 252
The therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Macrophage heterogeneity in respiratory diseases
Boorsma, C. E., Draijer, C., & Melgert, B. N. (2013) · Mediators of Inflammation · doi:10.1155/2013/769214 · Cited by 126
Shafaq-Zadah, M., Dransart, E., Hamitouche, I., Wunder, C., Chambon, V., Valades-Cruz, C. A., Leconte, L., Sarangi, N. K., Robinson, J., Bai, S.-K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64523-7 · Cited by 12
Metadata
- Authors
- Nishi, Y., Sano, H., Kawashima, T., Okada, T., Kuroda, T., Kikkawa, K., Kawashima, S., Tanabe, M., Goto, T., Matsuzawa, Y., Matsumura, R., Tomioka, H., Liu, F.-T., & Shirai, K.
- Venue
- Allergology International
- Publisher
- Japanese Society of Allergology
- Published
- 2007
- Volume
- 56
- Issue
- 1
- Pages
- 57-65
- ISSN
- 1323-8930 (ISSN-L)
- OpenAlex
- W1984439708
- Cited by
- 226
- References
- 5
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.